Vitamin E intake and quality of life in amyotrophic lateral sclerosis patients: a follow-up case series study.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder involving both upper and lower motor neurons, leading inexorably to death within a few years. Although our understanding of the pathogenesis of this disease has grown at a very fast rate in recent years, we do not yet have effective treatment options that can positively impact the quality of life (QoL) of these patients. Interestingly, increasing experimental evidence suggests that oxidative stress is involved in the pathogenesis of ALS and that vitamin E could reduce neuronal damage. Hence, in this observational study we determined the QoL in 33 ALS patients taking or not taking vitamin E supplementation (600 mg/day), using the Italian version of the Short-Form 36-Item Health Survey (SF-36). No differences were seen between the two groups of patients, therefore we do not recommend routine use of vitamin E in ALS patients, at least in the absence of randomised clinical trials specifically designed for addressing this issue.
Galbussera
A
A
Department of Neurology, S. Gerardo Hospital and University of Milano-Bicocca, Via Donizetti 106, I-20052, Monza (MI), Italy. galbuz@libero.it
Tremolizzo
L
L
Brighina
L
L
Testa
D
D
Lovati
R
R
Ferrarese
C
C
Cavaletti
G
G
Filippini
G
G
D000368:Aged; D000369:Aged, 80 and over; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D019587:Dietary Supplements; D005260:Female; D005500:Follow-Up Studies; D006306:Health Surveys; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use; D011788:Quality of Life; D019782:Riluzole / Q000627:therapeutic use; D014810:Vitamin E / Q000627:therapeutic use*; D014815:Vitamins / Q000627:therapeutic use*
D018696:Neuroprotective Agents; D014815:Vitamins; D014810:Vitamin E; D019782:Riluzole